Ana Clara Santos Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ana Clara Santos Costa has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Sura Wanessa Santos Rocha
Fundação Oswaldo Cruz, Brazil; Universidade Federal de Pernambuco, Brazil; Universidade de Pernambuco, Brazil
2 shared publications - Amanda Pinheiro de Barros Albuquerque
Campus Professor Cinobelina Elvas, Universidade Federal do Piauí , Bom Jesus, Piauí
1 shared publication - Anderson Felix Dos Santos
Department of Nursing Nova Esperança School of Nursing (FACENE) João Pessoa Paraíba Brazil
1 shared publication - Andre Machado Siqueira
Fundação Oswaldo Cruz, Brasil
1 shared publication - Andrea Dória Batista
Universidade Federal de Pernambuco
1 shared publication - Angela Luzia Branco Pinto Duarte
Universidade Federal de Pernambuco
1 shared publication
Latest Publications
- Open Access
- 14 October 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (10) , e70635
TIMP‐2 as a Potential Indicator of Persistent Arthralgia in Chikungunya: Evidence From a Brazilian Cohort Study
Chikungunya virus (CHIKV) infection can trigger a sustained inflammatory response, often leading to chronic musculoskeletal pain. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may contribute to the persistence of arthralgia through their involvement in joint tissue remodeling and degradation. This study aimed to evaluate the potential of MMPs and TIMPs as plasma biomarkers of persistent arthralgia in individuals diagnosed with Chikungunya Fever (CHIKF). A prospective cohort study was conducted using plasma samples from 133 CHIKF‐positive individuals recruited during the acute or post‐acute phases. Sociodemographic and clinical data were collected at outpatient visits. At 90 days post‐symptom onset, participants were assessed for persistent arthralgia using a self‐reported Visual Analog Scale (VAS) for joint pain and categorized into two groups: Recovered (VAS 0–3, n = 71) or Persistent Arthralgia (VAS 4–10, n = 62). Plasma levels of MMP‐2, MMP‐9, and TIMP‐2 were quantified using multiplex bead‐based ELISA (LegendPlex), while MMP‐1, MMP‐3, MMP‐14/MT1‐MMP, and TIMP‐1 were measured via sandwich ELISA. Plasma samples from 51 CHIKV‐negative individuals were used as controls. Statistical analyzes were performed using GraphPad Prism v9.0, IBM SPSS Statistics and Stata. Among post‐acute participants, lower MMP‐2 levels were significantly associated with recovery compared to those with persistent arthralgia and to controls. TIMP‐2 levels varied significantly across clinical outcomes, supporting its involvement in CHIKV‐induced pathology. Multivariate analysis identified swollen joints, skin rash, and elevated TIMP‐2 levels during the post‐acute phase as independent predictors of persistent arthralgia in the chronic phase. No significant differences were observed for MMP‐1, MMP‐3, MMP‐9, MMP‐14, or TIMP‐1. These findings suggest a potential role for TIMP‐2 and musculoskeletal manifestations as early indicators of chronic joint symptoms following CHIKV infection. Further studies are needed to validate these biomarkers and better understand the mechanisms underlying chronic Chikungunya‐related arthralgia across diverse populations.
- 14 October 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (10) , e70635
Open AccessTIMP‐2 as a Potential Indicator of Persistent Arthralgia in Chikungunya: Evidence From a Brazilian Cohort Study
Chikungunya virus (CHIKV) infection can trigger a sustained inflammatory response, often leading to chronic musculoskeletal pain. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) may contribute to the persistence of arthralgia through their involvement in joint tissue remodeling and degradation. This study aimed to evaluate the potential of MMPs and TIMPs as plasma biomarkers of persistent arthralgia in individuals diagnosed with Chikungunya Fever (CHIKF). A prospective cohort study was conducted using plasma samples from 133 CHIKF‐positive individuals recruited during the acute or post‐acute phases. Sociodemographic and clinical data were collected at outpatient visits. At 90 days post‐symptom onset, participants were assessed for persistent arthralgia using a self‐reported Visual Analog Scale (VAS) for joint pain and categorized into two groups: Recovered (VAS 0–3, n = 71) or Persistent Arthralgia (VAS 4–10, n = 62). Plasma levels of MMP‐2, MMP‐9, and TIMP‐2 were quantified using multiplex bead‐based ELISA (LegendPlex), while MMP‐1, MMP‐3, MMP‐14/MT1‐MMP, and TIMP‐1 were measured via sandwich ELISA. Plasma samples from 51 CHIKV‐negative individuals were used as controls. Statistical analyzes were performed using GraphPad Prism v9.0, IBM SPSS Statistics and Stata. Among post‐acute participants, lower MMP‐2 levels were significantly associated with recovery compared to those with persistent arthralgia and to controls. TIMP‐2 levels varied significantly across clinical outcomes, supporting its involvement in CHIKV‐induced pathology. Multivariate analysis identified swollen joints, skin rash, and elevated TIMP‐2 levels during the post‐acute phase as independent predictors of persistent arthralgia in the chronic phase. No significant differences were observed for MMP‐1, MMP‐3, MMP‐9, MMP‐14, or TIMP‐1. These findings suggest a potential role for TIMP‐2 and musculoskeletal manifestations as early indicators of chronic joint symptoms following CHIKV infection. Further studies are needed to validate these biomarkers and better understand the mechanisms underlying chronic Chikungunya‐related arthralgia across diverse populations.
- Open Access
- 10 December 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (12)
COVID-19 neurological manifestations: a narrative review on the mechanisms, pathogenesis, and clinical management
Coronaviruses are a large viral family, whose infections are recognized since 1960, varying from the common cold to more critical respiratory conditions. Regarding coronavirus 2019 (COVID-19), a wide spectrum of neurological manifestations among infected patients were reported, raising concerns whether Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) had tropism for the central nervous system. To clarify these questions, this bibliographic review was carried out by searching for articles based on national and international data during the period from December 2019 to June 2020. Thus, this review summarizes the current evidence on the transmission routes, focusing on the olfactory bulb and the hematogenic pathways, as well as the direct and indirect pathological mechanisms through which SARS-CoV-2 causes neurological damage. Moreover, clinical, laboratorial, and therapeutic aspects to manage patients with COVID-19 related neurological symptoms are outlined. Finally, development of treatments tackling specific structures and pathways related to viral entry and cardiovascular regulation on the brain are expected, in addition to monitoring of patients affected by the COVID-19 to assess long-term consequences on the nervous system.
- 10 December 2020
- Published by Research, Society and Development in Research, Society and Development
- Vol. 9 (12)
Open AccessCOVID-19 neurological manifestations: a narrative review on the mechanisms, pathogenesis, and clinical management
Coronaviruses are a large viral family, whose infections are recognized since 1960, varying from the common cold to more critical respiratory conditions. Regarding coronavirus 2019 (COVID-19), a wide spectrum of neurological manifestations among infected patients were reported, raising concerns whether Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) had tropism for the central nervous system. To clarify these questions, this bibliographic review was carried out by searching for articles based on national and international data during the period from December 2019 to June 2020. Thus, this review summarizes the current evidence on the transmission routes, focusing on the olfactory bulb and the hematogenic pathways, as well as the direct and indirect pathological mechanisms through which SARS-CoV-2 causes neurological damage. Moreover, clinical, laboratorial, and therapeutic aspects to manage patients with COVID-19 related neurological symptoms are outlined. Finally, development of treatments tackling specific structures and pathways related to viral entry and cardiovascular regulation on the brain are expected, in addition to monitoring of patients affected by the COVID-19 to assess long-term consequences on the nervous system.
- 1 January 2000
- Published by Elsevier in Journal of Hepatology
- Vol. 32, 181
Interferon improves liver fibrosis in patients with chronic hepatitis C
- 1 January 2000
- Published by Elsevier in Journal of Hepatology
- Vol. 32, 181
Interferon improves liver fibrosis in patients with chronic hepatitis C